Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 20/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 20/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 20/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16407950 | 0.94 | RXRA (0.89) | RXRANR1H2NR1H3NR1I2 | |
| Bms-852927 SCHEMBL779963 | 0.91 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL779280 | 0.90 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL30412305 | 0.90 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL30197815 | 0.89 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL779338 | 0.89 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL780880 | 0.88 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL19579159 | 0.87 | NR1H2 (0.94) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL781718 | 0.86 | NR1H2 (1.00) | RXRANR1H2NR1H3NR1I2 | |
| SCHEMBL779981 | 0.86 | NR1H2 (0.90) | RXRANR1H2NR1H3NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2435410-B1 | LXR MODULATORS | EXELIXIS PATENT CO LLC (US) | 2017-01-18 | — | — | EP | claimed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | claimed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | claimed |
| US-12502368-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2025-12-23 | — | — | US | disclosed |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | Asteroid Therapeutics (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240252458-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| US-11865094-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | THE ROCKEFELLER UNIVERSITY (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4218935-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4218935-A1 | LXRBETA AGONIST FOR THE TREATMENT OF CANCER | The Rockefeller University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163081-A1 | LXR MODULATORS | EXELIXIS PATENT COMPANY LLC (US) | 2014-06-12 | — | — | US | disclosed |
| WO-2014028461-A2 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2014-02-20 | — | — | WO | disclosed |
| WO-2014028461-A2 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY (US) | 2014-02-20 | — | — | WO | disclosed |
| US-8618154-B2 | LXR modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-12-31 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| US-20120071534-A1 | LXR MODULATORS | EXELIXIS, INC. | 2012-03-22 | — | — | US | disclosed |
| WO-2010138598-A2 | LXR MODULATORS | EXELIXIS, INC. (US) | 2010-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163081-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-11865094-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
| US-20230338314-A1 | METHODS FOR THE TREATMENT OF MYELOID DERIVED SUPPRESSOR CELLS RELATED DISORDERS | NR1H3, NR1H2, MCL1 | RXRA 20/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20240252458-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
| US-12502368-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | RXRA 2268/4885NR1H2 4537/4885NR1H3 4400/4885 |
| US-20120071534-A1 | LXR MODULATORS | NR1H3, NR1H2, NR1H4 | RXRA 10/4885NR1H2 2/4885NR1H3 1/4885 |
| US-20240293401-A1 | COMBINATION THERAPY WITH AN LXR AGONIST AND AN INHIBITOR COMPOUND | NR1H2, NR1H3, NR1H4 | RXRA 5/4885NR1H2 1/4885NR1H3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.